JP6343563B2 - 組織浸潤リンパ球の検出および測定方法 - Google Patents
組織浸潤リンパ球の検出および測定方法 Download PDFInfo
- Publication number
- JP6343563B2 JP6343563B2 JP2014547393A JP2014547393A JP6343563B2 JP 6343563 B2 JP6343563 B2 JP 6343563B2 JP 2014547393 A JP2014547393 A JP 2014547393A JP 2014547393 A JP2014547393 A JP 2014547393A JP 6343563 B2 JP6343563 B2 JP 6343563B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tissue
- lymphocytes
- cell
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 108
- 210000004698 lymphocyte Anatomy 0.000 title claims description 105
- 210000001519 tissue Anatomy 0.000 claims description 123
- 150000007523 nucleic acids Chemical class 0.000 claims description 84
- 102000039446 nucleic acids Human genes 0.000 claims description 81
- 108020004707 nucleic acids Proteins 0.000 claims description 81
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 44
- 108091093088 Amplicon Proteins 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 108091008874 T cell receptors Proteins 0.000 claims description 38
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 37
- 239000007787 solid Substances 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 36
- 210000003289 regulatory T cell Anatomy 0.000 claims description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 12
- 230000006798 recombination Effects 0.000 claims description 11
- 238000005215 recombination Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 238000012165 high-throughput sequencing Methods 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000004286 T(FH) Anatomy 0.000 claims 4
- 210000000447 Th1 cell Anatomy 0.000 claims 4
- 210000000068 Th17 cell Anatomy 0.000 claims 4
- 210000004241 Th2 cell Anatomy 0.000 claims 4
- 210000002378 Th9 Anatomy 0.000 claims 4
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 description 130
- 238000003199 nucleic acid amplification method Methods 0.000 description 81
- 230000003321 amplification Effects 0.000 description 80
- 238000012163 sequencing technique Methods 0.000 description 78
- 238000003752 polymerase chain reaction Methods 0.000 description 67
- 239000002773 nucleotide Substances 0.000 description 53
- 125000003729 nucleotide group Chemical group 0.000 description 53
- 210000003719 b-lymphocyte Anatomy 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 44
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 35
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 31
- 108091008875 B cell receptors Proteins 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 17
- 102000040430 polynucleotide Human genes 0.000 description 17
- 238000001574 biopsy Methods 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 15
- 238000013459 approach Methods 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 238000011160 research Methods 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 210000000207 lymphocyte subset Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000007403 mPCR Methods 0.000 description 7
- 230000000392 somatic effect Effects 0.000 description 7
- 206010069754 Acquired gene mutation Diseases 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 6
- 241001156002 Anthonomus pomorum Species 0.000 description 6
- 101150111062 C gene Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 230000037439 somatic mutation Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- -1 CD45RO Proteins 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004163 cytometry Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000012332 laboratory investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000019689 luncheon sausage Nutrition 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032392 Circadian-associated transcriptional repressor Human genes 0.000 description 1
- 101710130150 Circadian-associated transcriptional repressor Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008709 cellular rearrangement Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011273 incision biopsy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003826 marginal zone b cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Ecology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
本出願は2011年12月13日に出願された同時係属中の米国仮特許出願第61/570,192号の優先権を主張し、この出願は全体として参照により本明細書に組み入れられる。
固形腫瘍などの疾患罹患組織中に浸潤している異なるリンパ球サブセットの数および比率は、その疾患の予後と関係している場合が多い;例えば、Deschoolmeester et al, BMC Immunology, 11:19 (2010)(非特許文献1);Ohtani, Cancer Immunity, 7: 4 (2007)(非特許文献2);Yu et al, Laboratory Investigation, 86: 231-245 (2006)(非特許文献3);Diederichsen et al, Cancer Immunol. Immunother., 52: 423-428 (2003)(非特許文献4)など。残念ながら、免疫組織化学的検査またはフローサイトメトリーなどの利用可能な技術を用いたそのような量の測定は、難しく、大きな労働力を要し、かつ定常的な配備に適していない。
本発明の実施は、特記されない限り、当技術分野の技術の範囲内にある、分子生物学(組換え技法を含む)、バイオインフォマティクス、細胞生物学、および生化学の従来の技法および説明を使用することができる。このような従来の技法には、血液細胞のサンプリングおよび解析、核酸の配列決定および解析などが含まれるが、これらに限定されない。適切な技法の具体的な例は、本明細書における以下の実施例を参照することによって知ることができる。しかしながら、その他の同等な従来の手順もまた、当然ながら用いることができる。このような従来の技法および説明は、Genome Analysis: A Laboratory Manual Series (Vols. I-IV);PCR Primer: A Laboratory Manual;およびMolecular Cloning: A Laboratory Manual(いずれもCold Spring Harbor Laboratory Pressによる)などの標準的な実験室マニュアルにおいて見出すことができる。
本発明に従って、入手しやすい組織に由来するリンパ球をサブセットに分離し、これを解析してクロノタイプを決定し、次にこのクロノタイプを用いて、入手しやすさに劣る組織における異なるサブセットのリンパ球の数および/またはレベルを決定する;したがって、大部分の態様において、少なくとも1つは入手しやすい組織から、および少なくとも1つは入手しにくい組織からという、少なくとも2つの種類の試料を得る。いくつかの態様において、そこから試料が取得される入手しやすい組織には、末梢血、骨髄、リンパ液、滑液などが含まれるが、これらに限定されない。いくつかの態様において、そこから試料が取得される入手しやすさに劣るまたは入手しにくい組織は、固形腫瘍、自己免疫疾患と関連した炎症組織などの固形組織である。入手しやすさに劣る試料がそこから取得される例示的な固形腫瘍には、メラノーマ、結腸直腸、卵巣、胃、乳房、肝細胞、尿路上皮などが含まれるが、これらに限定されない。特に関心が高いのは、結腸直腸腫瘍およびメラノーマである。自己免疫疾患と関連している例示的な固形組織には、結合組織、関節結合組織、筋肉組織、皮膚、肺組織、小腸組織、結腸組織などが含まれるが、これらに限定されない。他の態様において、入手しやすい組織は末梢血であり、入手しやすさに劣る組織は、サンプリングする際に患者にかなりの苦痛をもたらす任意の組織である。例えば、そのような態様において、入手しやすさに劣る組織には、骨髄、リンパ液、滑液など、および先に開示されたような固形組織が含まれ得る。
本発明と併用してそこから核酸が抽出される固定組織試料(例えば、切除された腫瘍組織などに由来する)は、典型的には、固形腫瘍などの疾患関連組織に由来する、化学的に固定された組織試料である。本発明において用いられる固定組織試料を作製するために用いられる化学固定液には、アルデヒド、アルコール、および同様の試薬が含まれる。典型的には、本発明において用いられる固定組織試料は、ホルムアルデヒドまたはグルタルアルデヒドで固定され、特にホルマリン固定パラフィン包埋 (FFPE) 組織試料として提供される。本発明と共に使用するための核酸抽出技法の手引きは、以下の参考文献に開示されており、これらは参照により組み入れられる:Dedhia et al, Asian Pacific J. Cancer Prev., 8: 55-59 (2007);Okello et al, Analytical Biochemistry, 400: 110-117 (2010);Bereczki et al, Pathology Oncology Research, 13(3): 209-214 (2007);Huijsmans et al, BMC Research Notes, 3: 239 (2010);Wood et al, Nucleic Acids Research, 38(14): e151 (2010);Gilbert et al, PLosOne, 6: e537 (June 2007);Schweiger et al, PLosOne, 4(5): e5548 (May 2009)。加えて、製造業者の説明書を用いて本発明と共に使用することができる、固定組織からの核酸抽出を行うためのいくつかの市販のキットが存在する:AllPrep DNA/RNA FFPE Kit(Qiagen、San Diego, CA);Absolutely RNA FFPE Kit(Agilent、Santa Clara, CA);QuickExtract FFPE DNA Extraction Kit(Epicentre、Madison, WI);RecoverAll Total Nucleic Acid Isolation Kit for FFPE(Ambion、 Austin, TX)など。
1つの態様において、本発明により、入手しにくい組織に浸潤するB細胞のアイソタイプの同定が可能になる。Bリンパ球によって産生される免疫グロブリンのアイソタイプは、免疫グロブリンの定常領域の一部分をコードする核酸を含むように設計されたクロノタイプから決定され得る。したがって、本発明の1つの局面に従って、クロノタイプは、免疫グロブリン重鎖 (IgH) をコードするヌクレオチドの配列リードから構築される。本発明のこのようなクロノタイプは、VDJコード領域の一部分およびそれと関連する定常領域(またはC領域)の一部分を含む。アイソタイプは、C領域の部分をコードするヌクレオチド配列から決定される。1つの態様において、C領域をコードする部分はVDJコード領域と隣接しており、その結果、参照により本明細書に組み入れられるFaham and Willis、米国特許出願公開第2011/0207134号によって開示されているように、ポリメラーゼ連鎖反応法 (PCR) などの簡便な技法によって、単一の連続配列が増幅され得る。C領域をコードするクロノタイプの部分は、特徴的なアレルの存在によってアイソタイプを同定するために用いられる。1つの態様では、8〜100個のC領域コードヌクレオチドがクロノタイプ中に含まれる;別の態様では、8〜20個のC領域コードヌクレオチドがクロノタイプ中に含まれる。1つの態様において、このようなC領域コード部分は、以下でより十分に記載されるように、IgHコード配列の増幅中に取り込まれる。このような増幅では、上記の範囲内の数のC領域コードヌクレオチドが、結果として得られるアンプリコン中に取り込まれるように、1種または複数種のC領域プライマーを配置する。
標的核酸集団のアンプリコンは、様々な増幅技法により生成され得る。本発明の1つの局面においては、マルチプレックスPCRが、核酸の混合物、特に組換え免疫分子、例えばT細胞受容体またはそれらの一部分を含む混合物のメンバーを増幅するのに使用される。そのような免疫分子のマルチプレックスPCRを実施するための手引きは、参照により組み入れられる以下の参考文献において見出される:Faham and Willis、米国特許出願公開第2011/0207134号;Morley、米国特許第5,296,351号;Gorski、米国特許第5,837,447号;Dau、米国特許第6,087,096号;Von Dongen et al、米国特許出願公開第2006/0234234号;欧州特許公報EP 1544308B1等。
本発明の方法では、任意のハイスループット核酸配列決定技法を使用することができる。好ましくは、このような技法は、そこから少なくとも1000種のクロノタイプが決定され得る、および好ましくはそこから少なくとも10,000〜1,000,000種のクロノタイプが決定され得る大量の配列データを、費用に対して効果の高い方法で生成する能力を有する。DNA配列決定技法は、標識されたターミネーターまたはプライマーおよびスラブまたはキャピラリー中でのゲル分離を用いるジデオキシ配列決定反応(サンガー法)、可逆的に停止される標識ヌクレオチドを用いる合成による配列決定、パイロシークエンシング、454配列決定、標識オリゴヌクレオチドプローブのライブラリーに対するアレル特異的ハイブリダイゼーション、標識クローンのライブラリーに対するアレル特異的ハイブリダイゼーションおよびその後のライゲーションを用いる合成による配列決定、重合工程中における標識ヌクレオチドの組み込みのリアルタイムモニタリング、ポロニーシークエンシング、ならびにSOLiD配列決定を含む。分離された分子の配列決定は、最近になって、ポリメラーゼまたはリガーゼを用いる連続的または単回の伸長反応によって、およびプローブのライブラリーを用いる単回または連続的なディファレンシャルハイブリダイゼーションによって実証されている。これらの反応は、多くのクローン配列に対して並列で実施され、現在の商業利用においては1億超の配列の並列化が実現している。したがってこれらの配列決定アプローチは、T細胞受容体(TCR)および/またはB細胞受容体(BCR)のレパートリーの研究に使用することができる。
配列リードデータからのクロノタイプの構築は、一部、そのようなデータを生成するのに使用された配列決定法に依存しており、これは、方法が異なると、予想リード長およびデータ品質が異なるためである。1つのアプローチにおいて、解析用の配列リードデータの生成にSolexaシーケンサーが使用される。1つの態様において、少なくとも100万の鋳型分子をもたらすための少なくとも0.5〜1.0×106個のリンパ球を提供する試料が得られ、鋳型分子は、任意の増幅後に、対応する100万またはそれ以上の鋳型分子クローン集団(またはクラスター)をもたらし得る。Solexaアプローチを含む最もハイスループットな配列決定アプローチについては、配列決定の精度を増大させるべく高い冗長度で各鋳型配列が決定されるように、そのようなクラスターレベルでの過剰サンプリングが望ましい。Solexaベースでの実施について、好ましくは、各々独立した鋳型の配列は10回またはそれ以上決定される。予想リード長およびデータ品質が異なる他の配列決定アプローチについては、同等の配列決定精度のために異なる冗長度レベルが使用され得る。当業者は、上記のパラメータ、例えば試料サイズ、冗長度等が、特定の用途に関連する設計上の選択事項であることを認識している。
この実施例では、TCRβ鎖を解析する。解析は、TCRβ配列の増幅、配列決定、および解析を含む。1つのプライマーは、Cβ1およびCβ2の共通配列に相補的であり、全48種のVセグメントを増幅することができる34種のVプライマーが存在する。Cβ1またはCβ2は、J/C結合部から10位および14位の位置で互いに異なっている。Cβ1またはCβ2のプライマーは16bpの位置で終了し、Cβ1またはCβ2に対する優先性はない。34種のVプライマーを、Van Dongen等の米国特許出願公開第2006/0234234号(参照により本明細書に組み入れられる)に開示の元のプライマーセットから改変する。改変されたプライマーは、参照により本明細書に組み入れられるFahamらの米国特許出願公開第2010/0151471号に開示されている。
P7は、分子の固相増幅(クラスター形成)に用いられる。1分子当たり3件の配列リードを行う。100 bpの第1リードは、Illumina配列決定過程に適している融解温度を有するC'プライマーを用いて行う。第2リードは6 bp長のみであり、単に試料タグを同定するためのものである。これは、製造業者 (Illumina) によって提供されるタグプライマーを用いて生成される。最終リードは、やはり製造業者 (Illumina) によって提供されるRead 2プライマーである。このプライマーを用いて、第1PCR のVプライマー配列から開始する、Vセグメントにおける100 bpリードが生成される。
本明細書において他に具体的に規定されない限り、本明細書で用いられる核酸化学、生化学、遺伝学、および分子生物学の用語および記号は、当分野における標準的な論文および教科書、例えば、Kornberg and Baker, DNA Replication, Second Edition (W.H. Freeman, New York, 1992);Lehninger, Biochemistry, Second Edition (Worth Publishers, New York, 1975);Strachan and Read, Human Molecular Genetics, Second Edition (Wiley-Liss, New York, 1999);Abbas et al, Cellular and Molecular Immunology, 6th edition (Saunders, 2007)の用語および記号に従っている。
Claims (28)
- 固形組織に浸潤した、機能的サブセットに属するリンパ球を同定するための方法であって、
個体の入手しやすい組織に由来するリンパ球の試料を、少なくとも1つの機能的サブセットに選別すること;
前記少なくとも1つのサブセットから得られた組換え核酸分子を増幅して複数のアンプリコンを得ることと、生じた該複数のアンプリコンのハイスループットシーケンシングを実施して、各機能的サブセットの個々のリンパ球を識別するクロノタイプ配列のリストを提供することとによって、該入手しやすい組織に由来するリンパ球の機能的サブセットの各々についてクロノタイププロファイルを生成すること;
該固形組織の少なくとも1つの試料から少なくとも1つのクロノタイププロファイルを生成することであって、固形組織の前記少なくとも1つの試料から得られた組換え核酸分子を増幅して複数のアンプリコンを得ることと、生じた該複数のアンプリコンのハイスループットシーケンシングを実施して各試料中のクロノタイプ配列のリストを提供することとによって少なくとも1つのクロノタイププロファイルを生成すること;および
該入手しやすい組織由来の機能的サブセットのクロノタイプ配列のリストに存在する該固形組織由来のクロノタイプ配列を同定することであって、該機能的サブセットの各々についてのクロノタイププロファイルが、CDR3領域の少なくとも一部を含む少なくとも1000種のクロノタイプを含む、クロノタイプ配列を同定することによって、該入手しやすい組織から該固形組織へと浸潤した、機能的サブセットに属するリンパ球を同定すること、
を含み、
前記入手しやすい組織は、末梢血、骨髄、リンパ液、または滑液から選択され、
前記CDR3領域の少なくとも一部は、前記試料中の別個のリンパ球と1対1の対応を有する、
方法。 - リンパ球の前記少なくとも1つの機能的サブセットのうちの少なくとも1つが、細胞傷害性T細胞、ヘルパーT細胞、調節性T細胞、Th1 T細胞、Th2 T細胞、Th9 T細胞、Th17 T細胞、および/またはTfh T細胞を含む、請求項1に記載の方法。
- 前記同定することが、前記固形組織中の各機能的サブセットのリンパ球の数および/または比率を決定することをさらに含む、請求項2に記載の方法。
- 前記固形組織が固形腫瘍である、請求項3に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットが、調節性T細胞および細胞傷害性T細胞を含む、請求項4に記載の方法。
- 前記同定することが、前記固形腫瘍中の調節性T細胞対細胞傷害性T細胞の比率を決定することを含む、請求項5に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットが、抗原特異的T細胞の少なくとも1つのサブセットを含む、請求項3に記載の方法。
- 前記入手しやすい組織が前記個体の末梢血である、請求項1に記載の方法。
- 前記同定することが、前記少なくとも1つの機能的サブセットの各々におけるリンパ球の数を、そのそれぞれのクロノタイプをカウントすることによって数えることをさらに含む、請求項1に記載の方法。
- 前記固形組織の試料が、前記固形組織の異なる位置から取得された複数の組織試料を含む、請求項1に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットが、ヘルパーT細胞および細胞傷害性T細胞を含む、請求項1に記載の方法。
- ヘルパーT細胞がFoxP3 + 調節性T細胞である、請求項11に記載の方法。
- 細胞傷害性T細胞がCD8+マーカーによって同定され、かつ調節性T細胞がマーカーCD4+、CD25+(高)、およびCD127(低)によって同定される、請求項12に記載の方法。
- 前記固形組織が固形腫瘍である、請求項13に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットが、1つまたは複数の細胞表面マーカーまたは細胞内マーカーに基づいて別々の容器に選別される、請求項1に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットを選別することが、蛍光活性化セルソーター (FACS) を用いて実行される、請求項15に記載の方法。
- 前記クロノタイププロファイルの前記クロノタイプの各々が、T細胞受容体の組換え部分を含む、請求項1に記載の方法。
- 前記クロノタイププロファイルの前記クロノタイプの各々が、T細胞受容体β鎖をコードする核酸のV(D)J領域の少なくとも一部分を含む、請求項17に記載の方法。
- 前記クロノタイププロファイルの全てが、少なくとも106種のクロノタイプを含む、請求項18に記載の方法。
- 前記固形組織が、自己免疫疾患に罹患している固形組織である、請求項1に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットのうちの少なくとも1つが、細胞傷害性T細胞、ヘルパーT細胞、調節性T細胞、Th1 T細胞、Th2 T細胞、Th9 T細胞、Th17 T細胞、および/またはTfh T細胞より選択され、かつ前記同定することが、前記固形組織中の各機能的サブセットのリンパ球の数および/または比率を決定することをさらに含む、請求項20に記載の方法。
- リンパ球の前記少なくとも1つの機能的サブセットが、調節性T細胞、Th1 T細胞、Th2 T細胞、Th9 T細胞、Th17 T細胞、Tfh T細胞、および/または抗原特異的T細胞の1つの機能的サブセットを含む、請求項21に記載の方法。
- 前記固形組織が、結腸組織、小腸組織、皮膚、結合組織、皮下組織、肺組織、および腎臓組織からなる群より選択される、請求項21に記載の方法。
- 前記固形組織が正常組織であり、かつリンパ球の前記少なくとも1つの機能的サブセットのうちの少なくとも1つが、T細胞、細胞傷害性T細胞、ヘルパーT細胞、調節性T細胞、Th1 T細胞、Th2 T細胞、Th9 T細胞、Th17 T細胞、Tfh T細胞、および抗原特異的T細胞より選択され、かつ前記同定することが、前記固形組織中の各機能的サブセットのリンパ球の数および/または比率を決定することをさらに含む、請求項1に記載の方法。
- 該個体の入手しやすい組織に由来するリンパ球の試料を、少なくとも2つの機能的サブセットに選別することをさらに含む、請求項1に記載の方法。
- 該個体の入手しやすい組織に由来するリンパ球の試料を、少なくとも3つの機能的サブセットに選別することをさらに含む、請求項1に記載の方法。
- 該個体の入手しやすい組織に由来するリンパ球の試料を、少なくとも4つの機能的サブセットに選別することをさらに含む、請求項1に記載の方法。
- 該個体の入手しやすい組織に由来するリンパ球の試料を、少なくとも5つの機能的サブセットに選別することをさらに含む、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570192P | 2011-12-13 | 2011-12-13 | |
US61/570,192 | 2011-12-13 | ||
PCT/US2012/069310 WO2013090469A1 (en) | 2011-12-13 | 2012-12-12 | Detection and measurement of tissue-infiltrating lymphocytes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015501658A JP2015501658A (ja) | 2015-01-19 |
JP2015501658A5 JP2015501658A5 (ja) | 2017-01-26 |
JP6343563B2 true JP6343563B2 (ja) | 2018-06-13 |
Family
ID=48572527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014547393A Active JP6343563B2 (ja) | 2011-12-13 | 2012-12-12 | 組織浸潤リンパ球の検出および測定方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9499865B2 (ja) |
EP (2) | EP2791357B1 (ja) |
JP (1) | JP6343563B2 (ja) |
CN (1) | CN104114715A (ja) |
AU (1) | AU2012352364B2 (ja) |
CA (1) | CA2859002C (ja) |
ES (1) | ES2699653T3 (ja) |
SG (1) | SG11201403212RA (ja) |
WO (1) | WO2013090469A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9394567B2 (en) | 2008-11-07 | 2016-07-19 | Adaptive Biotechnologies Corporation | Detection and quantification of sample contamination in immune repertoire analysis |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
EP2364368B1 (en) | 2008-11-07 | 2014-01-15 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
ES2726702T3 (es) | 2009-01-15 | 2019-10-08 | Adaptive Biotechnologies Corp | Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales |
RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
CA2796822C (en) | 2010-05-07 | 2021-10-05 | The Board Of Trustees Of The Leland Standford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
AU2012325791B2 (en) | 2011-10-21 | 2018-04-05 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
CA2858070C (en) | 2011-12-09 | 2018-07-10 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
ES2662128T3 (es) | 2012-03-05 | 2018-04-05 | Adaptive Biotechnologies Corporation | Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes |
HUE029357T2 (en) | 2012-05-08 | 2017-02-28 | Adaptive Biotechnologies Corp | Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions |
US20160002731A1 (en) | 2012-10-01 | 2016-01-07 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
WO2014121272A2 (en) | 2013-02-04 | 2014-08-07 | Quake Stephen R | Measurement and comparison of immune diversity by high-throughput sequencing |
EP3611262B1 (en) | 2013-03-15 | 2020-11-11 | Lineage Biosciences, Inc. | Methods of sequencing the immune repertoire |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
ES2741740T3 (es) | 2014-03-05 | 2020-02-12 | Adaptive Biotechnologies Corp | Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
EP3132059B1 (en) | 2014-04-17 | 2020-01-08 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US10392663B2 (en) | 2014-10-29 | 2019-08-27 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
AU2015353581A1 (en) | 2014-11-25 | 2017-06-15 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
WO2016138122A1 (en) | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
WO2016161273A1 (en) | 2015-04-01 | 2016-10-06 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
CN106680513A (zh) * | 2017-02-24 | 2017-05-17 | 广东省人民医院(广东省医学科学院) | 抗cd4的抗体及抗cxcr5的抗体在制备评估慢性移植物抗宿主病中的试剂中的应用 |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
CN112005115A (zh) | 2018-02-12 | 2020-11-27 | 10X基因组学有限公司 | 表征来自单个细胞或细胞群体的多种分析物的方法 |
WO2019217758A1 (en) | 2018-05-10 | 2019-11-14 | 10X Genomics, Inc. | Methods and systems for molecular library generation |
US11603565B2 (en) * | 2018-06-15 | 2023-03-14 | Roche Sequencing Solutions, Inc. | System for identification of antigens recognized by T cell receptors expressed on tumor infiltrating lymphocytes |
CA3125762A1 (en) | 2019-01-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
CN111599411B (zh) * | 2020-06-08 | 2023-04-14 | 谱天(天津)生物科技有限公司 | 一种检测血液bcr重链和轻链的引物及免疫组库方法、应用 |
CA3214486A1 (en) | 2021-03-24 | 2022-09-29 | Genentech, Inc. | Efficient tcr gene editing in t lymphocytes |
Family Cites Families (320)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE3211263A1 (de) | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
DE3238353A1 (de) | 1982-10-15 | 1984-04-19 | Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verfahren zur simultanen quantitativen bestimmung der blutzellen und reagenz hierfuer |
US5189147A (en) | 1984-06-13 | 1993-02-23 | Massachusetts Institute Of Technology | Meterodimeric T lymphocyte receptor antibody |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3541033A1 (de) | 1985-11-19 | 1987-05-21 | Boehringer Mannheim Gmbh | Verfahren zur quantifizierung von zellpopulationen bzw. subpopulationen sowie hierfuer geeignetes reagenz |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4942124A (en) | 1987-08-11 | 1990-07-17 | President And Fellows Of Harvard College | Multiplex sequencing |
US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
US5667967A (en) | 1990-05-01 | 1997-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | T-cell receptor varible transcripts as disease related markers |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US5168038A (en) | 1988-06-17 | 1992-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | In situ transcription in cells and tissues |
US5296351A (en) | 1988-10-20 | 1994-03-22 | Alexander A. Morley | Method for diagnosis of monoclonality in leukaemia and lymphoma |
US5075217A (en) | 1989-04-21 | 1991-12-24 | Marshfield Clinic | Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences |
US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5298396A (en) | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
US5336598A (en) | 1989-11-15 | 1994-08-09 | National Jewish Center For Immunology And Respiratory Medicine | Method for diagnosing a superantigen caused pathologial condition via assay of T-cells |
US5126022A (en) | 1990-02-28 | 1992-06-30 | Soane Tecnologies, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
US6054034A (en) | 1990-02-28 | 2000-04-25 | Aclara Biosciences, Inc. | Acrylic microchannels and their use in electrophoretic applications |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
US5699798A (en) | 1990-08-10 | 1997-12-23 | University Of Washington | Method for optically imaging solid tumor tissue |
US5635354A (en) | 1991-01-09 | 1997-06-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system |
US5364759B2 (en) | 1991-01-31 | 1999-07-20 | Baylor College Medicine | Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats |
IE920447A1 (en) | 1991-02-12 | 1992-08-12 | Roussel Uclaf | NUCLEOTIDE SEQUENCES CODING FOR ß-CHAIN VARIABLE REGIONS OF¹HUMAN T-LYMPHOCYTE RECEPTORS, CORRESPONDING PEPTIDE SEGMENTS¹AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
JP3080178B2 (ja) | 1991-02-18 | 2000-08-21 | 東洋紡績株式会社 | 核酸配列の増幅方法およびそのための試薬キット |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5674679A (en) | 1991-09-27 | 1997-10-07 | Amersham Life Science, Inc. | DNA cycle sequencing |
US5981179A (en) | 1991-11-14 | 1999-11-09 | Digene Diagnostics, Inc. | Continuous amplification reaction |
US5213960A (en) | 1992-03-09 | 1993-05-25 | Tanox Biosystems, Inc. | Methods for selecting low frequency antigen-specific single B lymphocytes |
US5256542A (en) | 1992-03-09 | 1993-10-26 | Tanox Biosystems, Inc. | Selecting low frequency antigen-specific single B lymphocytes with correction for background noise |
US5837447A (en) | 1992-04-15 | 1998-11-17 | Blood Center Research Foundation, Inc., The | Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid |
US5498392A (en) | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
US5587128A (en) | 1992-05-01 | 1996-12-24 | The Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification devices |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
EP0753060A4 (en) | 1994-04-18 | 1999-11-24 | New York Society | PRESERVED T CELL RECEPTOR SEQUENCES |
US6001229A (en) | 1994-08-01 | 1999-12-14 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing microfluidic manipulations for chemical analysis |
US6090592A (en) | 1994-08-03 | 2000-07-18 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid on supports |
US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US5776737A (en) | 1994-12-22 | 1998-07-07 | Visible Genetics Inc. | Method and composition for internal identification of samples |
US6919434B1 (en) | 1995-02-20 | 2005-07-19 | Sankyo Co., Ltd. | Monoclonal antibodies that bind OCIF |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
WO1997013877A1 (en) | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
US6087096A (en) | 1995-11-13 | 2000-07-11 | Dau; Peter C. | Method of intrafamily fragment analysis of the T cell receptor α and β chain CDR3 regions |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US20020076725A1 (en) | 1996-03-13 | 2002-06-20 | Tomoko Toyosaki-Maeda | Human t cell clone specific for rheumatoid arthritis |
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
WO1997046706A1 (en) | 1996-06-03 | 1997-12-11 | University Of Alberta | Methods for detection of rearranged dna |
CA2257109C (en) | 1996-06-04 | 2009-10-06 | University Of Utah Research Foundation | Monitoring hybridization during pcr |
AU3878697A (en) | 1996-06-20 | 1998-02-02 | Cornell Research Foundation Inc. | Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors |
US6074827A (en) | 1996-07-30 | 2000-06-13 | Aclara Biosciences, Inc. | Microfluidic method for nucleic acid purification and processing |
DE69737028T2 (de) | 1996-09-06 | 2007-06-28 | Ortho-Mcneil Pharmaceutical, Inc. | Reinigung von antigenspezifischen t-zellen |
US5935793A (en) | 1996-09-27 | 1999-08-10 | The Chinese University Of Hong Kong | Parallel polynucleotide sequencing method using tagged primers |
GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
EP3034626A1 (en) | 1997-04-01 | 2016-06-22 | Illumina Cambridge Limited | Method of nucleic acid sequencing |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
AU736836B2 (en) | 1997-07-07 | 2001-08-02 | Medical Research Council | In vitro sorting method |
US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6803019B1 (en) | 1997-10-15 | 2004-10-12 | Aclara Biosciences, Inc. | Laminate microstructure device and method for making same |
WO1999020798A1 (en) | 1997-10-23 | 1999-04-29 | Exact Laboratories, Inc. | Methods for detecting contamination in molecular diagnostics using pcr |
US7351578B2 (en) | 1999-12-10 | 2008-04-01 | Invitrogen Corp. | Use of multiple recombination sites with unique specificity in recombinational cloning |
US6210910B1 (en) | 1998-03-02 | 2001-04-03 | Trustees Of Tufts College | Optical fiber biosensor array comprising cell populations confined to microcavities |
JP4262799B2 (ja) | 1998-04-16 | 2009-05-13 | 平田機工株式会社 | 生タイヤ供給方法 |
DE19833738A1 (de) | 1998-07-27 | 2000-02-03 | Michael Giesing | Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens |
US6787308B2 (en) | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
DE19844931C1 (de) | 1998-09-30 | 2000-06-15 | Stefan Seeger | Verfahren zur DNS- oder RNS-Sequenzierung |
AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
US6541608B1 (en) | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US6300070B1 (en) | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US20040209314A1 (en) | 1999-09-06 | 2004-10-21 | Institut National De La Sante Et De La Recherche Medicale France | Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA |
US6235483B1 (en) | 2000-01-31 | 2001-05-22 | Agilent Technologies, Inc. | Methods and kits for indirect labeling of nucleic acids |
JP2004505612A (ja) | 2000-03-31 | 2004-02-26 | ユニバーシティ・オブ・サザン・カリフォルニア | 食道腺ガンに関する後成的配列 |
AUPQ687600A0 (en) | 2000-04-13 | 2000-05-11 | Flinders Technologies Pty Ltd | A method of detection |
US20030207300A1 (en) | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
US6596492B2 (en) | 2000-07-11 | 2003-07-22 | Colorado State University Research Foundation | PCR materials and methods useful to detect canine and feline lymphoid malignancies |
US7567870B1 (en) | 2000-07-31 | 2009-07-28 | Institute For Systems Biology | Multiparameter analysis for predictive medicine |
US6939451B2 (en) | 2000-09-19 | 2005-09-06 | Aclara Biosciences, Inc. | Microfluidic chip having integrated electrodes |
ATE380883T1 (de) | 2000-10-24 | 2007-12-15 | Univ Leland Stanford Junior | Direkte multiplex charakterisierung von genomischer dna |
US6778724B2 (en) | 2000-11-28 | 2004-08-17 | The Regents Of The University Of California | Optical switching and sorting of biological samples and microparticles transported in a micro-fluidic device, including integrated bio-chip devices |
US7148040B2 (en) | 2001-02-20 | 2006-12-12 | University Of Georgia Research Foundation, Inc. | Method of rapid production of hybridomas expressing monoclonal antibodies on the cell surface |
US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
CA2487099A1 (en) | 2001-05-24 | 2002-11-28 | Bruce N. Wilkie | Methods for selecting and producing animals having a predicted level of immune response |
US20050260570A1 (en) | 2001-05-29 | 2005-11-24 | Mao Jen-I | Sequencing by proxy |
US6720144B1 (en) | 2001-06-21 | 2004-04-13 | Quest Diagnostics | Detection of clonal T-cell receptor-γ gene rearrangement by PCR/temporal temperature gradient gel electrophoresis (TTGE) |
CA2492220C (en) | 2001-07-15 | 2014-03-18 | Keck Graduate Institute | Nucleic acid amplification using nicking agents |
WO2003020983A1 (en) | 2001-08-30 | 2003-03-13 | Virginia Commonwealth University | Allele specific pcr for genotyping |
US7432084B2 (en) | 2001-08-31 | 2008-10-07 | Rosetta Inpharmatics Llc | Methods for preparing nucleic acid samples |
NZ531208A (en) | 2001-08-31 | 2005-08-26 | Avidex Ltd | Multivalent soluble T cell receptor (TCR) complexes |
AU2002341752B2 (en) | 2001-09-19 | 2008-04-03 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
EP1451340B1 (en) | 2001-11-09 | 2014-01-08 | Life Technologies Corporation | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
GB2382137A (en) | 2001-11-20 | 2003-05-21 | Mats Gullberg | Nucleic acid enrichment |
GB0128153D0 (en) | 2001-11-23 | 2002-01-16 | Bayer Ag | Profiling of the immune gene repertoire |
WO2003052101A1 (en) | 2001-12-14 | 2003-06-26 | Rosetta Inpharmatics, Inc. | Sample tracking using molecular barcodes |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
AU2003207528A1 (en) | 2002-01-09 | 2003-07-30 | Maxx Genetech Co. Ltd | Method of detecting t-cell proliferation for diagnosis of diseases by gene array |
US7157274B2 (en) | 2002-06-24 | 2007-01-02 | Cytonome, Inc. | Method and apparatus for sorting particles |
EP1511690A4 (en) | 2002-05-16 | 2007-10-24 | Univ Vanderbilt | TECHNIQUE FOR PREDICTING AUTOIMMUNE DISEASES |
US20060259248A1 (en) | 2002-07-01 | 2006-11-16 | Institut Pasteur | System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of peak data from an automated sequencer |
EP1517995A4 (en) | 2002-07-03 | 2007-07-11 | Inst Scient Res Inc | COMPOSITIONS AND METHODS FOR DETECTING THE EXPRESSION OF GENES OF THE VARIABLE HUMAN T-CELL RECEPTOR FAMILY |
ATE483469T1 (de) | 2002-07-12 | 2010-10-15 | Univ Johns Hopkins | Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren |
EP1552010B1 (en) | 2002-07-19 | 2010-06-09 | Althea Technologies, Inc. | Strategies for gene expression analysis |
US7459273B2 (en) | 2002-10-04 | 2008-12-02 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
EP1549764B1 (en) | 2002-10-11 | 2010-10-06 | Erasmus Universiteit Rotterdam | Nucleic acid amplification primers for pcr-based clonality studies |
CA2501873A1 (en) | 2002-10-11 | 2004-04-22 | The Regents Of The University Of California | A method for diagnosis and prognosis of multiple sclerosis |
WO2004044209A1 (en) | 2002-11-13 | 2004-05-27 | Monoquant Pty Ltd | A method of detection |
ATE536548T1 (de) | 2002-11-14 | 2011-12-15 | Vivalis | Mikrowell-array-chip zum nachweis eines antigenspezifischen lymphozyten, verfahren zum nachweis eines antigenspezifischen lymphozyten und verfahren zur klonierung eines antigenrezeptorgens eines antigenspezifischen lymphozyten |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
WO2004063706A2 (en) | 2003-01-08 | 2004-07-29 | Maxx Genetech Co., Ltd. | Method of detecting over-expression of t-cell receptor genes by real-time pcr |
WO2005003375A2 (en) | 2003-01-29 | 2005-01-13 | 454 Corporation | Methods of amplifying and sequencing nucleic acids |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
WO2004096985A2 (en) | 2003-04-24 | 2004-11-11 | Mayo Foundation For Medical Education And Research | Methods for assessing biologic diversity |
AU2003902299A0 (en) | 2003-05-13 | 2003-05-29 | Flinders Medical Centre | A method of analysing a marker nucleic acid molecule |
US20070105105A1 (en) | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
US20050010030A1 (en) | 2003-07-02 | 2005-01-13 | Zang Jingwu Z. | T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis |
EP1641809B2 (en) | 2003-07-05 | 2018-10-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
US20060228350A1 (en) | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
US20050048498A1 (en) | 2003-08-29 | 2005-03-03 | Applera Corporation | Compositions, methods, and kits for assembling probes |
US7365179B2 (en) | 2003-09-09 | 2008-04-29 | Compass Genetics, Llc | Multiplexed analytical platform |
TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
FR2863274B1 (fr) | 2003-12-05 | 2012-11-16 | Commissariat Energie Atomique | Procede d'evaluation quantitative d'un rearrangement ou d'une recombinaison genetique ciblee d'un individu et ses applications. |
US20070238099A1 (en) | 2003-12-08 | 2007-10-11 | Cohen Irun R | Antigen Receptor Variable Region Typing |
DE60326052D1 (de) | 2003-12-15 | 2009-03-19 | Pasteur Institut | Ermittlung des Repertoires von B-Lymphozyten Populationen |
US20080166718A1 (en) | 2003-12-15 | 2008-07-10 | Institut Pasteur | Repertoire determination of a lymphocyte B population |
US20070160994A1 (en) | 2003-12-15 | 2007-07-12 | Institut Pasteur | Repertoire determination of a lymphocyte b population |
US7709262B2 (en) | 2004-02-18 | 2010-05-04 | Trustees Of Boston University | Method for detecting and quantifying rare mutations/polymorphisms |
US20060046258A1 (en) | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
WO2005084134A2 (en) | 2004-03-04 | 2005-09-15 | Dena Leshkowitz | Quantifying and profiling antibody and t cell receptor gene expression |
JP4480423B2 (ja) | 2004-03-08 | 2010-06-16 | 独立行政法人科学技術振興機構 | 免疫細胞クローンの拡大の有無の判定方法 |
DE102004016437A1 (de) | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen |
US20050250147A1 (en) | 2004-05-10 | 2005-11-10 | Macevicz Stephen C | Digital profiling of polynucleotide populations |
JP2007536939A (ja) | 2004-05-14 | 2007-12-20 | アモークス インコーポレーティッド | 免疫細胞バイオセンサーおよびその使用方法 |
EP1598429A1 (en) | 2004-05-19 | 2005-11-23 | Amplion Ltd. | Detection of amplicon contamination during PCR exhibiting two different annealing temperatures |
GB0412973D0 (en) | 2004-06-10 | 2004-07-14 | Celltech R&D Ltd | Identification of antibody producing cells |
US20060020397A1 (en) | 2004-07-21 | 2006-01-26 | Kermani Bahram G | Methods for nucleic acid and polypeptide similarity search employing content addressable memories |
CN101087890A (zh) | 2004-07-26 | 2007-12-12 | 帕拉列勒生物科学公司 | 多个基因组的同时分析 |
US20060094018A1 (en) | 2004-08-03 | 2006-05-04 | Bauer A R Jr | Discovery and a method for the early detection of pancreatic cancer and other disease conditions |
US7820382B2 (en) | 2004-08-03 | 2010-10-26 | Bauer A Robert | Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation |
DE602005020799D1 (de) | 2004-08-05 | 2010-06-02 | Genentech Inc | Humanisierte anti-cmet-antagonisten |
WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
EP1812563B1 (en) | 2004-10-29 | 2013-04-10 | Benaroya Research Institute at Virginia Mason | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use |
US7966988B2 (en) | 2005-01-11 | 2011-06-28 | Exxonmobil Research And Engineering Company | Method for controlling soot induced lubricant viscosity increase |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
FR2881436B1 (fr) | 2005-02-03 | 2007-04-27 | Commissariat Energie Atomique | Procede de determination de la diversite des lymphocytes t dans un echantillon biologique |
US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
EP1848994A2 (en) | 2005-02-16 | 2007-10-31 | Wyeth | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia |
US7537894B2 (en) | 2005-03-02 | 2009-05-26 | The University Of Chicago | Methods and kits for monitoring Barrett's metaplasia |
US20060216737A1 (en) | 2005-03-10 | 2006-09-28 | John Bodeau | Methods for multiplex amplification |
EP1856293A2 (en) | 2005-03-16 | 2007-11-21 | Compass Genetics, Llc | Methods and compositions for assay readouts on multiple analytical platforms |
ES2404311T3 (es) | 2005-04-12 | 2013-05-27 | 454 Life Sciences Corporation | Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda |
WO2006116155A2 (en) | 2005-04-21 | 2006-11-02 | The Regents Of The University Of California | A method for diagnosis and prognosis of multiple sclerosis subtypes |
US20060263789A1 (en) | 2005-05-19 | 2006-11-23 | Robert Kincaid | Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using |
US7208795B2 (en) | 2005-05-24 | 2007-04-24 | Atmel Corporation | Low-cost, low-voltage single-layer polycrystalline EEPROM memory cell integration into BiCMOS technology |
US8445194B2 (en) | 2005-06-15 | 2013-05-21 | Callida Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
US20090264299A1 (en) | 2006-02-24 | 2009-10-22 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
WO2007008759A2 (en) | 2005-07-07 | 2007-01-18 | Hematologics, Inc. | Methods for detecting and confirming minimal disease in a cancer patient |
US20070020640A1 (en) | 2005-07-21 | 2007-01-25 | Mccloskey Megan L | Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis |
GB0521521D0 (en) | 2005-10-21 | 2005-11-30 | Medical Res Council | Diagnostic methods and kits |
GB0522310D0 (en) | 2005-11-01 | 2005-12-07 | Solexa Ltd | Methods of preparing libraries of template polynucleotides |
US20070105165A1 (en) | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
US7375211B2 (en) | 2005-11-18 | 2008-05-20 | Kou Zhong C | Method for detection and quantification of T-cell receptor Vβ repertoire |
US8137936B2 (en) | 2005-11-29 | 2012-03-20 | Macevicz Stephen C | Selected amplification of polynucleotides |
US7537897B2 (en) | 2006-01-23 | 2009-05-26 | Population Genetics Technologies, Ltd. | Molecular counting |
US7544473B2 (en) | 2006-01-23 | 2009-06-09 | Population Genetics Technologies Ltd. | Nucleic acid analysis using sequence tokens |
AU2007222798A1 (en) | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
ES2546848T3 (es) | 2006-03-10 | 2015-09-29 | Epigenomics Ag | Un método para identificar una muestra biológica para el análisis de la metilación |
DK2002017T3 (en) | 2006-04-04 | 2015-09-07 | Keygene Nv | High-capacity detection of molecular markers based on restriction fragments |
US20100323401A1 (en) | 2006-05-11 | 2010-12-23 | Lewis George K | General method for generating human antibody responses in vitro |
WO2007136518A2 (en) | 2006-05-17 | 2007-11-29 | Torrey Pines Institute For Molecular Studies | Treatment of autoimmune disorders |
CA2653256C (en) | 2006-05-25 | 2018-08-28 | Institute For Advanced Study | Methods for identifying sequence motifs, and applications thereof |
US7833716B2 (en) | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
EP2027253A4 (en) | 2006-06-12 | 2014-04-30 | Pacific Biosciences California | SUBSTATES FOR EFFECTING ANALYSIS REACTIONS |
US20100027896A1 (en) | 2006-06-28 | 2010-02-04 | Amir Geva | Automated application interaction using a virtual operator |
AU2007269408A1 (en) | 2006-06-30 | 2008-01-10 | Applied Biosystems, Llc. | Reversible terminator nucleotides and methods of use |
WO2008108803A2 (en) | 2006-07-13 | 2008-09-12 | Amaox, Ltd. | Immune cell biosensors and methods of using same |
US8394590B2 (en) | 2006-08-02 | 2013-03-12 | California Institute Of Technology | Capture agents and related methods and systems for detecting and/or sorting targets |
US20080274904A1 (en) | 2006-08-10 | 2008-11-06 | Niall Anthony Gormley | Method of target enrichment |
WO2008026927A2 (en) | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
US20100035764A1 (en) | 2006-09-26 | 2010-02-11 | St. Jude Children's Research Hospital | Methods and compositions for monitoring t cell receptor diversity |
WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
JP5026047B2 (ja) | 2006-10-18 | 2012-09-12 | 株式会社膠原病研究所 | 自己免疫疾患の発症に関わる自己応答性t細胞またはt細胞受容体の同定方法、およびその利用 |
EP2102367A2 (en) | 2006-11-09 | 2009-09-23 | XDX, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
US7862999B2 (en) | 2007-01-17 | 2011-01-04 | Affymetrix, Inc. | Multiplex targeted amplification using flap nuclease |
PL2121920T3 (pl) | 2007-03-01 | 2012-01-31 | Symphogen As | Sposób klonowania pokrewnych przeciwciał |
WO2008147879A1 (en) | 2007-05-22 | 2008-12-04 | Ryan Golhar | Automated method and device for dna isolation, sequence determination, and identification |
CN101720359A (zh) | 2007-06-01 | 2010-06-02 | 454生命科学公司 | 从多重混合物中识别个别样本的系统和方法 |
US8454906B2 (en) | 2007-07-24 | 2013-06-04 | The Regents Of The University Of California | Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions |
US7901889B2 (en) | 2007-07-26 | 2011-03-08 | Pacific Biosciences Of California, Inc. | Molecular redundant sequencing |
ITRM20070429A1 (it) | 2007-08-06 | 2009-02-07 | Uni Cattolica Del Sacro Cuor E | Mezzi per la diagnosi la prevenzione e la cura dell'artrite reumatoide. |
CN104307581B (zh) | 2007-08-09 | 2017-04-12 | 诺思可有限公司 | 关联的多参数单细胞测定及残余生物材料回收的方法和装置 |
US8268564B2 (en) | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
US20100285984A1 (en) | 2007-09-28 | 2010-11-11 | Wettstein Peter J | Assessing t cell repertoires |
US7960116B2 (en) | 2007-09-28 | 2011-06-14 | Pacific Biosciences Of California, Inc. | Nucleic acid sequencing methods and systems |
CA2704499C (en) | 2007-11-07 | 2020-03-10 | Genentech, Inc. | Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
WO2009070767A2 (en) | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
EP2062982A1 (fr) | 2007-11-26 | 2009-05-27 | ImmunID | Procédé d'étude de la diversité combinatoire V(D)J |
CN101225441B (zh) | 2007-12-05 | 2010-12-01 | 浙江大学 | 一种检测克隆特异性t淋巴细胞tcr bv cdr3基因组成的方法 |
US20100021894A1 (en) | 2007-12-20 | 2010-01-28 | Northwestern University | Nanoparticle-Based Colorimetric Detection Of Cysteine |
US8621502B2 (en) | 2007-12-21 | 2013-12-31 | Microsoft Corporation | Obtaining user reactions to video |
US7767400B2 (en) | 2008-02-03 | 2010-08-03 | Helicos Biosciences Corporation | Paired-end reads in sequencing by synthesis |
EP2088432A1 (en) | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
CN104031984A (zh) | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
CN102007408A (zh) | 2008-02-28 | 2011-04-06 | 俄亥俄州立大学研究基金会 | 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途 |
US20090226975A1 (en) | 2008-03-10 | 2009-09-10 | Illumina, Inc. | Constant cluster seeding |
TW200938840A (en) | 2008-03-12 | 2009-09-16 | Emo Biomedicine Corp | A method for in vitro study of immune modulation using pig blood cell |
US8143007B2 (en) | 2008-03-13 | 2012-03-27 | National Institute Of Immunology | Nested primer sets for amplifying mouse immunoglobulin variable gene segments |
EP2274449B1 (en) | 2008-03-28 | 2015-12-23 | Pacific Biosciences of California, Inc. | Methods for nucleic acid sequencing |
ATE530497T1 (de) | 2008-03-31 | 2011-11-15 | Sony Deutschland Gmbh | Verfahren zur herstellung einer membran mit konischer pore |
DK2281065T3 (en) | 2008-04-16 | 2015-10-05 | Hudsonalpha Inst For Biotechnology | PROCEDURE TO EVALUATE AND COMPARE IMMUNE REPERTOIRS |
US8911948B2 (en) | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
EP2277049A4 (en) | 2008-05-09 | 2012-05-30 | Univ Duke | AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER |
US9068181B2 (en) | 2008-05-23 | 2015-06-30 | The General Hospital Corporation | Microfluidic droplet encapsulation |
WO2009145925A1 (en) | 2008-05-30 | 2009-12-03 | Massachusetts Institute Of Technology | Compositions and methods for spatial separation and screening of cells |
WO2009151628A2 (en) | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
AP2011005546A0 (en) | 2008-06-25 | 2011-02-28 | Baylor Res Intitute | Blood transcriptional signature of mycobacterium tuberculosis infection. |
US8394583B2 (en) | 2008-07-24 | 2013-03-12 | The Board Of Regents Of The University Of Texas System | VH4 codon signature for multiple sclerosis |
US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
AU2009297108B2 (en) | 2008-09-23 | 2015-02-12 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
US8699361B2 (en) | 2008-09-30 | 2014-04-15 | Qualcomm Incorporated | Out-of-synchronization handling method and apparatus |
US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
US8546128B2 (en) | 2008-10-22 | 2013-10-01 | Life Technologies Corporation | Fluidics system for sequential delivery of reagents |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8691510B2 (en) | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US20140234835A1 (en) | 2008-11-07 | 2014-08-21 | Sequenta, Inc. | Rare clonotypes and uses thereof |
EP2364368B1 (en) | 2008-11-07 | 2014-01-15 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
US9394567B2 (en) | 2008-11-07 | 2016-07-19 | Adaptive Biotechnologies Corporation | Detection and quantification of sample contamination in immune repertoire analysis |
US20110105343A1 (en) | 2008-11-21 | 2011-05-05 | Emory University | Systems Biology Approach Predicts Immunogenicity of Vaccines |
US8367330B2 (en) | 2008-12-22 | 2013-02-05 | Quest Diagnostics Investments Incorporated | Methods for detecting TCR-gamma gene rearrangement |
EP2384367A4 (en) | 2008-12-30 | 2013-07-10 | Janssen Biotech Inc | SERUM MARKERS TO PREDICT THE CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH MORBUS BECHTEREW |
ES2726702T3 (es) | 2009-01-15 | 2019-10-08 | Adaptive Biotechnologies Corp | Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales |
AU2010206843B2 (en) | 2009-01-20 | 2015-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell gene expression for diagnosis, prognosis and identification of drug targets |
US20100323348A1 (en) | 2009-01-31 | 2010-12-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process |
US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
US8673627B2 (en) | 2009-05-29 | 2014-03-18 | Life Technologies Corporation | Apparatus and methods for performing electrochemical reactions |
RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
US20120058902A1 (en) | 2009-06-25 | 2012-03-08 | Livingston Robert J | Method of measuring adaptive immunity |
US8497071B2 (en) | 2009-06-29 | 2013-07-30 | California Institute Of Technology | Isolation of unknown rearranged T-cell receptors from single cells |
WO2011035870A1 (en) | 2009-09-22 | 2011-03-31 | Roche Diagnostics Gmbh | Determination of kir haplotypes associated with disease |
US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
US9315857B2 (en) | 2009-12-15 | 2016-04-19 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse label-tags |
US8545248B2 (en) | 2010-01-07 | 2013-10-01 | Life Technologies Corporation | System to control fluid flow based on a leak detected by a sensor |
KR101323827B1 (ko) | 2010-01-08 | 2013-10-31 | 키스트 유럽 에프게엠베하 | 강직성척추염 진단용 프라이머 및 이를 이용한 강직성 척추염 진단 방법 |
GB201000375D0 (en) | 2010-01-09 | 2010-02-24 | Univ Cardiff | T Cell clonotypes |
WO2011106738A2 (en) | 2010-02-25 | 2011-09-01 | Fred Hutchinson Cancer Research Center | Use of tcr clonotypes as biomarkers for disease |
EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
SG185128A1 (en) | 2010-05-06 | 2012-12-28 | Sequenta Inc | Monitoring health and disease status using clonotype profiles |
CA2796822C (en) | 2010-05-07 | 2021-10-05 | The Board Of Trustees Of The Leland Standford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
US20130123120A1 (en) | 2010-05-18 | 2013-05-16 | Natera, Inc. | Highly Multiplex PCR Methods and Compositions |
WO2011156707A2 (en) | 2010-06-11 | 2011-12-15 | Life Technologies Corporation | Alternative nucleotide flows in sequencing-by-synthesis methods |
EP2623613B8 (en) | 2010-09-21 | 2016-09-07 | Population Genetics Technologies Ltd. | Increasing confidence of allele calls with molecular counting |
EP3447155A1 (en) | 2010-09-30 | 2019-02-27 | Raindance Technologies, Inc. | Sandwich assays in droplets |
WO2012048341A1 (en) | 2010-10-08 | 2012-04-12 | President And Fellows Of Harvard College | High-throughput single cell barcoding |
ES2730951T3 (es) | 2010-10-08 | 2019-11-13 | Harvard College | Secuenciación inmune de alto rendimiento |
EP2633069B1 (en) | 2010-10-26 | 2015-07-01 | Illumina, Inc. | Sequencing methods |
EP2635679B1 (en) | 2010-11-05 | 2017-04-19 | Illumina, Inc. | Linking sequence reads using paired code tags |
WO2012083069A2 (en) | 2010-12-15 | 2012-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and monitoring of cell clonality |
ES2615733T3 (es) | 2010-12-16 | 2017-06-08 | Gigagen, Inc. | Métodos para el análisis masivo paralelo de ácidos nucleicos en células individuales |
EP2659408B1 (en) | 2010-12-29 | 2019-03-27 | Life Technologies Corporation | Time-warped background signal for sequencing-by-synthesis operations |
US10146906B2 (en) | 2010-12-30 | 2018-12-04 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
US8759036B2 (en) | 2011-03-21 | 2014-06-24 | Affymetrix, Inc. | Methods for synthesizing pools of probes |
DK3246416T3 (da) | 2011-04-15 | 2024-09-02 | Univ Johns Hopkins | Sikkert sekventeringssystem |
HUE062102T2 (hu) | 2011-05-24 | 2023-09-28 | BioNTech SE | Individualizált vakcinák a rák ellen |
WO2013033721A1 (en) | 2011-09-02 | 2013-03-07 | Atreca, Inc. | Dna barcodes for multiplexed sequencing |
WO2013036459A2 (en) | 2011-09-09 | 2013-03-14 | Sequenta, Inc. | Sequence-based measures of immune response |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US20140256592A1 (en) | 2011-10-11 | 2014-09-11 | Sequenta, Inc. | Determining responsiveness of autoimmune patients to dmard treatment |
AU2012325791B2 (en) | 2011-10-21 | 2018-04-05 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US20150252422A1 (en) | 2011-11-04 | 2015-09-10 | Sequenta Llc | T-cell receptor clonotypes shared among ankylosing spondylitis patients |
US20140336059A1 (en) | 2011-12-05 | 2014-11-13 | Sequenta, Inc. | Clonotypes as biometric specimen tags |
EP2788507A4 (en) | 2011-12-09 | 2015-07-08 | Sequenta Inc | METHOD FOR MEASURING IMMUNE ACTIVATION |
CA2858070C (en) | 2011-12-09 | 2018-07-10 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US20150031553A1 (en) | 2011-12-13 | 2015-01-29 | Sequenta, Inc. | Method of measuring immune activation |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
JP2015504661A (ja) | 2011-12-20 | 2015-02-16 | シーケンタ インコーポレイテッド | 免疫レパートリー解析による、濾胞性リンパ腫からびまん性大細胞型b細胞リンパ腫への形質転換のモニタリング |
US20150031555A1 (en) | 2012-01-24 | 2015-01-29 | Gigagen, Inc. | Method for correction of bias in multiplexed amplification |
US11177020B2 (en) | 2012-02-27 | 2021-11-16 | The University Of North Carolina At Chapel Hill | Methods and uses for molecular tags |
WO2013131074A1 (en) | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
ES2662128T3 (es) | 2012-03-05 | 2018-04-05 | Adaptive Biotechnologies Corporation | Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes |
WO2013134302A1 (en) | 2012-03-05 | 2013-09-12 | Sequenta, Inc. | Monitoring immune responsiveness to cancer vaccination |
US20150038346A1 (en) | 2012-03-05 | 2015-02-05 | Sequenta, Inc. | Monitoring immune responsiveness to cancer vaccination |
AU2013246050B2 (en) | 2012-04-13 | 2017-03-16 | Adaptive Biotechnologies Corp. | Detection and quantitation of sample contamination in immune repertoire analysis |
WO2013158936A1 (en) | 2012-04-20 | 2013-10-24 | Sequenta, Inc | Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia |
HUE029357T2 (en) | 2012-05-08 | 2017-02-28 | Adaptive Biotechnologies Corp | Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions |
US20150247201A1 (en) | 2012-05-31 | 2015-09-03 | Malek Faham | Predicting relapse of chronic lymphocytic leukemia patients treated by allogeneic stem cell transplantation |
US20130324422A1 (en) | 2012-06-04 | 2013-12-05 | Sequenta, Inc. | Detecting disease-correlated clonotypes from fixed samples |
WO2013188471A2 (en) | 2012-06-11 | 2013-12-19 | Sequenta, Inc. | Method of sequence determination using sequence tags |
EP2861761A1 (en) | 2012-06-15 | 2015-04-22 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
SG11201500313YA (en) | 2012-07-24 | 2015-02-27 | Sequenta Inc | Single cell analysis using sequence tags |
JP2015524282A (ja) | 2012-08-10 | 2015-08-24 | シーケンタ インコーポレイテッド | 配列タグを用いた高感度突然変異検出 |
DE112013004650T5 (de) | 2012-09-24 | 2015-06-18 | Cb Biotechnologies, Inc. | Multiplexpyrosequenzierung unter Verwendung nichtinterferierender, rauschbeendender Polynukleotididentifikationstags |
CA2888520A1 (en) | 2012-10-19 | 2014-04-24 | Sequenta, Inc. | Monitoring diffuse large b-cell lymphoma from peripheral blood samples |
WO2014062945A1 (en) | 2012-10-19 | 2014-04-24 | Sequenta, Inc. | Monitoring clonotypes of plasma cell proliferative disorders in peripheral blood |
CA2888524A1 (en) | 2012-10-22 | 2014-05-01 | Sequenta, Inc. | Monitoring mantle cell lymphoma clonotypes in peripheral blood after immunotransplant |
JP6513035B2 (ja) | 2013-02-22 | 2019-05-15 | アダプティヴ バイオテクノロジーズ コーポレーション | 希少クロノタイプおよびその用途 |
US20140255944A1 (en) | 2013-03-08 | 2014-09-11 | Sequenta, Inc. | Monitoring treatment-resistant clones in lymphoid and myeloid neoplasms by relative levels of evolved clonotypes |
US20140255929A1 (en) | 2013-03-11 | 2014-09-11 | Sequenta, Inc. | Mosaic tags for labeling templates in large-scale amplifications |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
WO2015013461A2 (en) | 2013-07-26 | 2015-01-29 | Sequenta, Inc. | Cancer vaccination with antigen evolution |
AU2014337063A1 (en) | 2013-10-18 | 2016-05-19 | Adaptive Biotechnologies Corp. | Predicting patient responsiveness to immune checkpoint inhibitors |
US20150218656A1 (en) | 2014-02-03 | 2015-08-06 | Adaptive Biotechnologies Corp. | Methods for detection and diagnosis of a lymphoid malignancy using high throughput sequencing |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
-
2012
- 2012-11-29 US US13/688,414 patent/US9499865B2/en active Active
- 2012-12-12 SG SG11201403212RA patent/SG11201403212RA/en unknown
- 2012-12-12 EP EP12856834.2A patent/EP2791357B1/en active Active
- 2012-12-12 EP EP18205899.0A patent/EP3460076A1/en active Pending
- 2012-12-12 AU AU2012352364A patent/AU2012352364B2/en active Active
- 2012-12-12 CA CA2859002A patent/CA2859002C/en active Active
- 2012-12-12 JP JP2014547393A patent/JP6343563B2/ja active Active
- 2012-12-12 CN CN201280069638.XA patent/CN104114715A/zh active Pending
- 2012-12-12 WO PCT/US2012/069310 patent/WO2013090469A1/en unknown
- 2012-12-12 ES ES12856834T patent/ES2699653T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP2791357A4 (en) | 2015-08-05 |
US20130150252A1 (en) | 2013-06-13 |
WO2013090469A1 (en) | 2013-06-20 |
ES2699653T3 (es) | 2019-02-12 |
CA2859002A1 (en) | 2013-06-20 |
CA2859002C (en) | 2018-10-16 |
EP2791357A1 (en) | 2014-10-22 |
EP3460076A1 (en) | 2019-03-27 |
EP2791357B1 (en) | 2018-11-14 |
SG11201403212RA (en) | 2014-10-30 |
US9499865B2 (en) | 2016-11-22 |
AU2012352364A1 (en) | 2014-07-03 |
JP2015501658A (ja) | 2015-01-19 |
CN104114715A (zh) | 2014-10-22 |
AU2012352364B2 (en) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6343563B2 (ja) | 組織浸潤リンパ球の検出および測定方法 | |
JP6302847B2 (ja) | 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定 | |
JP6383789B2 (ja) | 配列タグによる大規模生体分子解析 | |
JP6085249B2 (ja) | 複雑なアンプリコンの配列解析 | |
AU2013246050B2 (en) | Detection and quantitation of sample contamination in immune repertoire analysis | |
JP2015534806A (ja) | 末梢血試料によるびまん性大細胞型b細胞性リンパ腫のモニタリング関連出願の相互参照本出願は、2012年10月19日出願の米国特許仮出願第61/716,270号の利益を主張するものであり、当該出願は参照により本明細書にその全体が組み込まれる。 | |
JP2015501644A (ja) | 免疫活性化を測定する方法 | |
US20150038346A1 (en) | Monitoring immune responsiveness to cancer vaccination | |
US20140336059A1 (en) | Clonotypes as biometric specimen tags | |
JP2015504661A (ja) | 免疫レパートリー解析による、濾胞性リンパ腫からびまん性大細胞型b細胞リンパ腫への形質転換のモニタリング | |
US20140356339A1 (en) | Sequence-based measures of immune response | |
JP2015532123A (ja) | 免疫移植後の末梢血におけるマントル細胞リンパ腫のクローン型のモニタリング | |
US20130324422A1 (en) | Detecting disease-correlated clonotypes from fixed samples | |
JP2015535178A (ja) | 末梢血における形質細胞増殖障害のクロノタイプのモニタリング | |
WO2013134302A1 (en) | Monitoring immune responsiveness to cancer vaccination | |
WO2013188471A2 (en) | Method of sequence determination using sequence tags |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150619 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20151118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151210 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151125 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20160217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161128 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20161214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171228 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180501 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180521 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6343563 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |